MDCX
Medicus Pharma·NASDAQ
--
--(--)
--
--(--)
MDCX fundamentals
During Q4 2025, Medicus Pharma (MDCX) reported revenue of --, a YoY change of 0.00%. Net income was -8.18M, a YoY change of -131.43%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Operating Expenses | 402.53K -- | 255.69K -- | 226.81K -- | -- -- | 1.71M +324.15% | 3.55M +1289.88% | 2.33M +929.16% | 3.59M -- | 5.13M +200.25% | 6.02M +69.28% | 15.43M +560.87% | 7.79M +117.28% | 34.36M -- |
Selling, General and Administrative Expenses | 69.11K -- | 206.12K -- | 186.42K -- | -- -- | 1.39M +1905.38% | 2.28M +1004.54% | 1.77M +849.54% | 2.22M -- | 3.12M +125.12% | 4.58M +101.02% | 5.02M +183.83% | 5.20M +134.19% | 17.92M -- |
General and Administrative Expenses | -- -- | 206.12K -- | 186.42K -- | -- -- | 1.39M -- | 2.28M +1004.54% | 1.77M +849.54% | 2.22M -- | 3.12M +125.12% | 4.58M +101.02% | 5.02M +183.83% | 5.20M +134.19% | 17.92M -- |
Research and Development Expenses | 333.42K -- | 49.58K -- | 40.40K -- | -- -- | 321.38K -3.61% | 1.28M +2476.21% | 564.14K +1296.57% | 1.37M -- | 2.01M +524.26% | 1.44M +12.72% | 10.40M +1743.90% | 2.59M +89.79% | 16.44M -- |
Operating Income | -402.53K -- | -255.69K -- | -226.81K -- | -- -- | -1.71M -324.15% | -3.55M -1289.88% | -2.33M -929.16% | -3.59M -- | -5.13M -200.25% | -6.02M -69.28% | -15.43M -560.87% | -7.79M -117.28% | -34.36M -- |
Non-Operating Income (Loss) | -81.39K -- | -232.97K -- | -2.74M -- | -- -- | 0 +100.00% | -79.03K +66.08% | 55.51K +102.03% | 48.90K -- | 23.87K -- | -160.00K -102.46% | -554.97K -1099.70% | -393.96K -905.69% | -1.09M -- |
Gain (Loss) on Change in Fair Value | -- -- | 152.81K -- | 264.12K -- | -- -- | -- -- | 0 -100.00% | 0 -100.00% | 0 -- | -- -- | -200.00K -- | -383.82K -- | 0 -- | -- -- |
Other Non-Operating Income (Loss) | -- -- | 0 -- | -2.55M -- | -- -- | -- -- | -- -- | 0 +100.00% | 0 -- | -- -- | -- -- | -182.72K -- | -121.13K -- | -- -- |
Net Interest Expense | 81.39K -- | 385.79K -- | 450.34K -- | -- -- | 0 -100.00% | 79.03K -79.52% | -55.51K -112.33% | -48.90K -- | -23.87K -- | -40.00K -150.62% | -11.57K +79.15% | 272.82K +657.96% | 197.38K -- |
Interest Expense | -- -- | 385.79K -- | 450.34K -- | -- -- | -- -- | 79.03K -79.52% | -- -- | -23.51K -- | -- -- | -- -- | -- -- | 197.38K +939.53% | -- -- |
Interest Income | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | 55.51K -- | 25.39K -- | 23.87K -- | 40.00K -- | 11.57K -79.15% | -75.44K -397.18% | -- -- |
Pretax Income From Continuing Operations | -483.92K -- | -488.67K -- | -2.96M -- | -1.38M -- | -1.71M -252.82% | -3.63M -643.42% | -2.28M +23.11% | -3.54M -156.55% | -5.10M -198.85% | -6.18M -70.01% | -15.98M -601.32% | -8.18M -131.43% | -35.44M -- |
Net Income | -483.92K -- | -488.67K -- | -2.96M -- | -1.38M -- | -1.71M -252.82% | -3.63M -643.42% | -2.28M +23.11% | -3.54M -156.55% | -5.10M -198.85% | -6.18M -70.01% | -15.98M -601.32% | -8.18M -131.43% | -35.44M -- |
Net Income Attributable to Minority Interests | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | -77 -- | -69 -- | -- -- |
Net Income Attributable to Owners of the Company | -483.92K -- | -488.67K -- | -2.96M -- | -- -- | -1.71M -252.82% | -3.63M -643.42% | -2.28M +23.11% | -3.54M -- | -5.10M -198.85% | -6.18M -70.01% | -15.98M -601.32% | -8.18M -131.43% | -35.44M -- |
Other Adjustments | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 4.95M -- | 6.88M -- | -- -- |
Net Income Attributable to Common Stockholders | -483.92K -- | -488.67K -- | -2.96M -- | -- -- | -1.71M -252.82% | -3.63M -643.42% | -2.28M +23.11% | -3.54M -- | -5.10M -198.85% | -6.18M -70.01% | -20.94M -818.74% | -15.07M -326.04% | -47.28M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 10.83K -- | -21.56K -- | -- -- |
Total Comprehensive Income | -483.92K -- | -488.67K -- | -2.96M -- | -1.38M -- | -1.71M -252.82% | -3.63M -643.42% | -2.28M +23.11% | -3.54M -156.55% | -5.10M -198.85% | -6.18M -70.01% | -20.93M -818.27% | -3.25M +8.06% | -35.46M -- |
Total Comprehensive Income Attributable to Minority Interests | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 75 -- | -225 -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -483.92K -- | -- -- | -2.96M -- | -- -- | -1.71M -252.82% | -3.63M -- | -2.28M +23.11% | -3.54M -- | -5.10M -198.85% | -6.18M -70.01% | -20.93M -818.27% | -3.25M +8.06% | -35.45M -- |
Basic EPS | -0.13 -- | -0.26 -- | -1.47 -- | -- -- | -0.21 -61.54% | -0.44 -69.23% | -0.24 +83.67% | -3.17 -- | -0.42 -100.00% | -0.43 +2.27% | -1.12 -366.67% | -2.07 +34.70% | -4.04 -- |
Basic EPS from Continuing Operations | -- -- | -0.26 -- | -1.47 -- | -- -- | -0.21 -- | -0.44 -69.23% | -0.24 +83.67% | -- -- | -0.42 -100.00% | -0.43 +2.27% | -1.12 -366.67% | -- -- | -- -- |
Diluted EPS | -0.13 -- | -0.26 -- | -1.47 -- | -- -- | -0.21 -61.54% | -0.44 -69.23% | -0.24 +83.67% | -- -- | -0.42 -100.00% | -0.43 +2.27% | -1.12 -366.67% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -0.26 -- | -1.47 -- | -- -- | -0.21 -- | -0.44 -69.23% | -0.24 +83.67% | -- -- | -0.42 -100.00% | -0.43 +2.27% | -1.12 -366.67% | -- -- | -- -- |
You can ask Aime
What guidance did Medicus Pharma's management provide for the next earnings period?What is Medicus Pharma's latest dividend and current dividend yield?What is Medicus Pharma's gross profit margin?What is the revenue and EPS growth rate for Medicus Pharma year over year?Did Medicus Pharma beat or miss consensus estimates last quarter?What were the key takeaways from Medicus Pharma’s earnings call?What does Medicus Pharma do and what are its main business segments?What is the market's earnings forecast for Medicus Pharma next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
